Ocata Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 77   

Articles published

OCAT 6.14 -0.06 (-0.97%)
price chart
Advanced Cell Technology Changes Name to Ocata Therapeutics
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc., (OTCBB: OCAT) today announced the change of its company name to Ocata Therapeutics, Inc., effective immediately. The change, which has been approved by the Company's ...
Related articles »  
The Butterfly Effect: Advanced Cell Technology Becomes Ocata Therapeutics ...
Ocata Therapeutics has entered an optimal moment in its developmental life cycle to initiate a long position. Prior to the as yet unknown date of up-list to the NASDAQ, which will occur with an accompanying equity raise, there is reason to believe the ...
Latest Updates on Ocata Therapeutics Inc (OTCMKTS:OCAT)  Equities Focus (registration)
Related articles »  
Ocata Therapeutics Licenses Induced Pluripotent Stem Cell Technology from ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Ocata Therapeutics, Inc. (�Ocata� or �the Company�; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology�, today announced that it has entered into a definitive agreement with Allele ...
Ocata Therapeutics (OCAT) Enters iPSC Licensing Agreement with Allele Biotech  StreetInsider.com
Ocata Therapeutics Receives Two New Patents for Immune-modulatory Cell ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Ocata Therapeutics, Inc. (�Ocata� or �the Company�; OTCBB: OCAT), a leader in the field of Regenerative OphthalmologyTM, today announced that the United States Patent and Trademark Office (USPTO) issued ...
2015 Brings Mixed Results For Ocata Therapeutics Inc (OTCMKTS:OCAT)  Traders350
Should you place a bet on Ocata Therapeutics?
This brings us to Ocata Therapeutics. The company calls itself a "leader in regenerative medicine." What is that, and on what basis is Advanced Cell a leader in this field?
Related articles »  
Analyst Recommendation on Shares: Ocata Therapeutics Inc , Ocwen Financial ...
In the latest statement by the brokerage house, Maxim Group downgrades its outlook on Ocata Therapeutics Inc (NASDAQ:OCAT).
Related articles »  
Ocata Therapeutics, Inc. Files SEC Form SC 13G, Statement of Acquisition of ...
By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a U.S.
Ocata Therapeutics To Trade On Nasdaq Global Market: Can The Bulls Finally ...
After months, if not years for some, Ocata shareholders were pleasantly surprised by the after-hours filing of the Form 8-A on February 23, 2015 by Ocata Therapeutics (NASDAQ:OCAT), which provides for registration of certain classes of securities ...
Ocata Therapeutics to Present at 2015 Cowen Health Care Conference  MarketWatch
Ocata Therapeutics Inc (OTCMKTS:OCAT) Is Rewarded With Two New Immune ...  Traders350
Form SC 13G/A Ocata Therapeutics, Inc. Filed by: Aronson Gary D
Check the appropriate box to designate the Rule pursuant to which this Schedule is filed. �, Rule 13d-1(b). x, Rule 13d-1(c). �, Rule 13d-1(d).
Ocata Therapeutics Receives Regulatory Guidance from European Medicines ...
Ocata Therapeutics, Inc. (�Ocata�; NASDAQ: OCAT), a leader in the field of regenerative ophthalmology, today announced that the company has received written formal guidance from the European Medicines Agency (EMA) related to the advancement of its ...